CN106008277A - Novel metformin hydrochloride and preparing method thereof - Google Patents
Novel metformin hydrochloride and preparing method thereof Download PDFInfo
- Publication number
- CN106008277A CN106008277A CN201610409379.0A CN201610409379A CN106008277A CN 106008277 A CN106008277 A CN 106008277A CN 201610409379 A CN201610409379 A CN 201610409379A CN 106008277 A CN106008277 A CN 106008277A
- Authority
- CN
- China
- Prior art keywords
- metformin hydrochloride
- hydrochloric acid
- hydrochloride
- preparation
- metformin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the technical field of medicine crystallization, and particularly relates to novel metformin hydrochloride and a preparing method thereof. Metformin-hydrochloride raw material medicine is selected as medicine API, and the preparing method of the crystal includes the solution volatilization method and the cooling crystallization method. According to the novel metformin hydrochloride and the preparing method thereof, the preparing method and the operation condition are simple, and the prepared product is high in yield and purity; the medicine has the stable physicochemical property, and the treating effect on II-type diabetes mellitus is reserved.
Description
Technical field
The invention belongs to pharmaceutical technology field, specifically, relate to hydrochlorate of a kind of metformin and preparation method thereof.
Background technology
Metformin hydrochloride (Metformin Hydrochloride), its chemical entitled 1,1-Dimethylbiguanide hydrochloride,
Structural formula is as follows:
Metformin hydrochloride is biguanides, for treating the patients with NIDDM of non-insulin-dependent, especially
Obesity and companion hyperinsulinemia person, be characterized in not promoting the secretion of insulin, but promote the tissue picked-up to glucose；
Not only there is hypoglycemic activity with this medicine, also lose weight and the effect of hyperinsulinemia.Can be with sulfonylurea blood sugar lowering
Medicine, small intestinal glycosidase inhibitor or thiazolidinediones antidiabetic drug share, and the most alone effect is more preferable.Can also be used for islets of langerhans
The patient of extract for treating, to reduce the consumption of insulin.It addition, it can also be substantially in blood pressure lowering and blood glutathione and liver
Mg2+Concentration, and then the liver protecting.
The form of medical compounds is important, the character of medicine such as dissolubility, intrinsic dissolution, draws moist and stability
Etc. there is significant difference, and these character may have influence on stability and the clinical efficacy of product.Meanwhile, the solid of medicine
Form is likely to affect mobility, Packing character and compressibility etc., then affects preparation technology and product quality.Therefore, tool is selected
Having the medical solid form of more satisfactory physicochemical property is the key of product development.
Summary of the invention
It is an object of the invention to provide a kind of novel Metformin, this crystal formation preparation method is simple, and chemistry is steady
Qualitative excellent.
A kind of two metformin hydrochloride, molecular formula is C4H12Cl2N5, structural formula is:
Two metformin hydrochloride as claimed in claim 1, X-powder diffractogram at 7.2 ± 0.2 °, 13.1 ± 0.2 °,
14.7±0.2°,16.9±0.2°,20.1±0.2°,21.2±0.2°,22.1±0.2°,22.4±0.2°,26.8±0.2°,
30.2 ± 0.2 °, 32.8 ± 0.2 ° exist series of features peak.
Two metformin hydrochloride according to claim 1, wherein, the cell parameter of described compound is as follows:
Unit cell dimension:
A() equal to 7.2 ± 0.1
B() equal to 5.8 ± 0.1
C() equal to 12.7 ± 0.1
Volume is equal to 513 ± 30
Space group P2 (1)
Density is 1.31 ± 0.01g/cm3。
The preparation method of foregoing two metformin hydrochloride, including: metformin hydrochloride is suspended in organic solvent/
In concentrated hydrochloric acid solution or certain density hydrochloric acid solution, heating makes described metformin hydrochloride dissolve, slow cooling crystallize, will analysis
The crystal gone out carries out filtering or centrifugation being dried, and i.e. obtains two metformin hydrochloride；Or, metformin hydrochloride is existed
Organic solvent/concentrated hydrochloric acid solution or certain density hydrochloric acid solution balance, is filtrated to get filtrate and volatilizees, be dried to obtain two
Metformin hydrochloride.
Described preparation method, is preferably: described in preparation reaction, organic solvent is selected from methanol, ethanol, dimethyl
Sulfoxide, isopropanol, acetone, N,N-dimethylformamide, DMAC N,N' dimethyl acetamide, oxolane, acetonitrile one or more.
Described organic solvent is 90:10 to 0:100 with the volume ratio of concentrated hydrochloric acid, it is preferable that for 90:10-50:50, concentrated hydrochloric acid is quality
Mark is 37% commercially available concentrated hydrochloric acid.During crystallize, rate of temperature fall is 5-30 DEG C/h.
Present invention also offers the pharmaceutical composition of two described metformin hydrochloride.Present invention also offers described two
Metformin hydrochloride or described pharmaceutical composition have the medicinal usage of related disorders in preparation for treating type Ⅱdiabetes mellitus.
Specifically, the novel crystal forms of metformin hydrochloride of the present invention, named two metformin hydrochloride, this compound thing
X-ray powder diagram be included in the diffraction maximum at following 10 or more 2 θ values: .2 ± 0.2 °, 13.1 ±
0.2°,14.7±0.2°,16.9±0.2°,21.2±0.2°,22.1±0.2°,22.4±0.2°,26.8±0.2°,30.2±
0.2°,32.8±0.2°.The X-powder diagram of this compound is substantially consistent with shown in Fig. 1.
The present invention provides the preparation method of two metformin hydrochloride of aforementioned stable.The present invention provides protection aforementioned stable
The pharmaceutical composition of two metformin hydrochloride.Two metformin hydrochloride of the present invention, fusing point is 188 DEG C, has as description is attached
X-ray powder diffraction spectrum shown in Fig. 1.It is understood that in test process, due to by many factors (such as test
The processing method of sample, instrument, test parameter, test operation etc. when the granularity of sample, test) impact, same crystal formation institute
The X-ray powder diffraction spectrum recorded go out peak position or peak intensity has certain difference.In X-ray powder diffraction spectrum
The experimental error of diffraction maximum 2 θ value can be ± 0.2 °.In one embodiment of the present invention, two hydrochloric acid two that the present invention provides
First biguanide, its differential scanning calorimetry analysis chart has endothermic peak at 220-250 DEG C, it is highly preferred that have endothermic peak, base at 242 DEG C
In basis consistent with shown in Fig. 2.
Two metformin hydrochloride that the present invention provides, its cell parameter is as follows:
Unit cell dimension:
A() equal to 7.2 ± 0.1
B() equal to 5.8 ± 0.1
C() equal to 12.7 ± 0.1
Volume is equal to 513 ± 30
Space group P2 (1)
Density is 1.31 ± 0.01g/cm3。
Present invention also offers the preparation method of above-mentioned two metformin hydrochloride, including: metformin hydrochloride is suspended in
In organic solvent/concentrated hydrochloric acid solution (90/10-0/100V/V) or certain density hydrochloric acid solution, heating makes described hydrochloride
Biguanide is dissolved, and carries out the crystal of precipitation filtering or centrifugation being dried, i.e. obtains two metformin hydrochloride；Or, will
Metformin hydrochloride balances in organic solvent/concentrated hydrochloric acid solution or certain density hydrochloric acid solution, is filtrated to get filtrate and carries out
Volatilization, obtains two metformin hydrochloride；Here, described organic solvent is for can make metformin hydrochloride molten in a heated condition
The solvent solved and can be miscible with water.
In the embodiment of this method, the preparation method of above-mentioned two metformin hydrochloride that the present invention provides, wherein, institute
State the metformin being suspended in organic solvent/concentrated hydrochloric acid solution (90/10-0/100V/V) and Chinese patent can be used
CN104788345A prepares.
In embodiments of the invention, described organic solvent can be selected from methanol, ethanol, dimethyl sulfoxide, isopropanol,
Acetone, N,N-dimethylformamide, DMAC N,N' dimethyl acetamide, oxolane, acetonitrile one or more.Reality in the present invention
Executing in scheme, organic solvent can be 90/10-0/100 with the volume ratio of concentrated hydrochloric acid, it is preferable that for 90/10-50/50.At this
In the embodiment of invention, described heating can be to be heated to 30 ~ 100 DEG C, it is therefore preferable to is heated to 50 ~ 80 DEG C.In the present invention
Embodiment in, the speed of described slow cooling is 5-30 DEG C/h.In embodiments of the invention, described hydrochloric acid two
First biguanide refers to the mono-hydrochloric salts of metformin.The invention provides the medicine comprising metformin hydrochloride two metformin hydrochloride
Compositions, can make solid orally ingestible, such as tablet, powder agent, capsule and pill；Oral liquid can also be made, as
Suspending agent, Emulsion, syrup and lytic agent.These preparations can containing conventional various excipient, as aromatic, preservative,
Wetting agent and edulcorant etc., it is also possible to containing conventional functional excipients, such as diluent (glycerol), binding agent, (many methyl are fine
Dimension element etc.), dispersant (sodium carbonate, calcium etc.), lubricant (stearate), filler (starch, saccharide), absorption enhancer (season
Ammonium compounds) and absorbent (Kaolin)；Unguentum external can also be made；It is equally applicable to make intravenous injection.
Two metformin hydrochloride of the present invention, have good physics and chemical stability, it is easy to industrialized production, for one
The new hydrochlorate of pharmaceutically acceptable, stable metformin.
Accompanying drawing explanation
Fig. 1: show the X-ray powder diagram of the present invention two metformin hydrochloride；
Fig. 2: show the mono-crystalline structures figure of the present invention two metformin hydrochloride；
Fig. 3: show thermogravimetric (TGA) analysis chart of the present invention two metformin hydrochloride；
Fig. 4: show means of differential scanning calorimetry (DSC) analysis chart of the present invention two metformin hydrochloride.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further detailed explanation, but example below is not interpreted as limiting
The present invention, under the method premise of the present invention, the simple transformation to the present invention falls within protection scope of the present invention.Experiment is concrete
Process is as follows:
Embodiment 1: under room temperature condition, adds flasks by each to metformin hydrochloride (1.0g) and pure methanol and 37% concentrated hydrochloric acid 5 milliliters
In, stirring 2h, after filtration, stay to obtain the volatilization of filtrate sealer, gained crystal is dried, and obtains two metformin hydrochloride.
Embodiment 2: metformin hydrochloride (10g) is suspended in methanol/concentrated hydrochloric acid solution (5ml/5ml), is heated to 50
DEG C described metformin hydrochloride is made to dissolve, 20 DEG C/h program crystallisation by cooling, carry out filtering or centrifugation by the crystal of precipitation
And be dried, i.e. obtain two metformin hydrochloride.
Embodiment 3: metformin hydrochloride (5g) is suspended in methanol/concentrated hydrochloric acid solution (5ml/5ml), is heated to 50 DEG C
Make described metformin hydrochloride dissolve, 20 DEG C/h program crystallisation by cooling, carry out the crystal of precipitation filtering or centrifugation also
It is dried, i.e. obtains two metformin hydrochloride.
Embodiment 4: metformin hydrochloride (10g) is suspended in methanol/concentrated hydrochloric acid solution (5ml/5ml), is heated to 50
DEG C described metformin hydrochloride is made to dissolve, 10 DEG C/h program crystallisation by cooling, carry out filtering or centrifugation by the crystal of precipitation
And be dried, i.e. obtain two metformin hydrochloride.
Embodiment 5: metformin hydrochloride (10g) is suspended in methanol/concentrated hydrochloric acid solution (5ml/5ml), is heated to 50
DEG C described metformin hydrochloride is made to dissolve, 20 DEG C/h program crystallisation by cooling, carry out filtering or centrifugation by the crystal of precipitation
And be dried, i.e. obtain two metformin hydrochloride.
Fig. 1: show the X-ray powder diagram of the present invention two metformin hydrochloride；Fig. 2: show disalt of the present invention
The mono-crystalline structures figure of acid metformin；Fig. 3: show thermogravimetric (TGA) analysis chart of the present invention two metformin hydrochloride；Fig. 4:
It show means of differential scanning calorimetry (DSC) analysis chart of the present invention two metformin hydrochloride.
From Fig. 1-2: the present invention two metformin hydrochloride has distinctive characteristic diffraction peak, with former metformin hydrochloride
Significantly different, for being different from the novel crystal forms of metformin hydrochloride；And the how salt acid molecule of a part in its lattice.By scheming
3 understand: the decomposition temperature of the present invention two metformin hydrochloride is 219.4 DEG C, the decomposition temperature (240 DEG C) of relatively metformin hydrochloride
Decrease.As shown in Figure 4: the fusing point of the present invention two metformin hydrochloride is 242.5 DEG C, the fusing point of relatively metformin hydrochloride
(230 DEG C) have raised.
The present invention two metformin hydrochloride remains the original structure of metformin molecule, i.e. remains it to type Ⅱdiabetes mellitus
Therapeutic effect.Meanwhile, the invention provides another crystal form of Metformin, and it is acid, molten to change it
The physicochemical properties such as Xie Du, fusing point, provide a new research for the expansion in terms of solid preparation of the hydrochloric acid drug class
Method.
Claims (9)
1. two metformin hydrochloride, is characterized in that, molecular formula is C4H12Cl2N5, structural formula is:
。
Two metformin hydrochloride the most as claimed in claim 1, it is characterised in that: X-powder diffractogram at 7.2 ± 0.2 °,
13.1±0.2°,14.7±0.2°,16.9±0.2°,20.1±0.2°,21.2±0.2°,22.1±0.2°,22.4±0.2°,
26.8 ± 0.2 °, 30.2 ± 0.2 °, 32.8 ± 0.2 ° exist series of features peak.
Two metformin hydrochloride the most according to claim 1, wherein, the cell parameter of described compound is as follows:
Unit cell dimension:
A() equal to 7.2 ± 0.1
B() equal to 5.8 ± 0.1
C() equal to 12.7 ± 0.1
Volume is equal to 513 ± 30
Space group P2 (1)
Density is 1.31 ± 0.01g/cm3。
4., according to the preparation method of two described metformin hydrochloride arbitrary in claim 1 ~ 3, it is characterized in that, including: by salt
Acid metformin is suspended in organic solvent/concentrated hydrochloric acid solution or certain density hydrochloric acid solution, and heating makes described hydrochloride
Biguanide is dissolved, slow cooling crystallize, carries out the crystal of precipitation filtering or centrifugation being dried, i.e. obtains two hydrochloride
Biguanide；Or, metformin hydrochloride is balanced in organic solvent/concentrated hydrochloric acid solution or certain density hydrochloric acid solution, filters
Obtain filtrate to volatilize, be dried to obtain two metformin hydrochloride.
Preparation method the most according to claim 4, it is characterised in that: preparation reaction described in organic solvent selected from methanol,
Ethanol, dimethyl sulfoxide, isopropanol, acetone, N,N-dimethylformamide, DMAC N,N' dimethyl acetamide, oxolane, acetonitrile
One or more.
Preparation method the most according to claim 6, it is characterised in that: described organic solvent with the volume ratio of concentrated hydrochloric acid is
90:10 to 0:100, it is preferable that for 90:10-50:50, concentrated hydrochloric acid be mass fraction be 37% commercially available concentrated hydrochloric acid.
Preparation method the most according to claim 6, it is characterised in that: during crystallize, rate of temperature fall is 5-30 DEG C/h.
8. the pharmaceutical composition of two metformin hydrochloride described in any one in claim 1 ~ 3.
9. in claim 1 ~ 3 any one require described in two metformin hydrochloride or medicine group as claimed in claim 8
Compound has the medicinal usage of related disorders in preparation for treating type Ⅱdiabetes mellitus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610409379.0A CN106008277A (en) | 2016-06-12 | 2016-06-12 | Novel metformin hydrochloride and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610409379.0A CN106008277A (en) | 2016-06-12 | 2016-06-12 | Novel metformin hydrochloride and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106008277A true CN106008277A (en) | 2016-10-12 |
Family
ID=57091061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610409379.0A Pending CN106008277A (en) | 2016-06-12 | 2016-06-12 | Novel metformin hydrochloride and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106008277A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017195086A1 (en) * | 2016-05-10 | 2017-11-16 | Sarath Kumar Kamavarapu | Salts of n,n-dimethylbiguanide and preparation methods thereof |
| CN108864100A (en) * | 2018-08-02 | 2018-11-23 | 中国海洋大学 | A kind of salt, preparation method and the crystal structure of mercaptopurine and melbine |
| WO2022148053A1 (en) * | 2021-01-05 | 2022-07-14 | 海南海力制药有限公司 | Purification method for metformin hydrochloride, metformin hydrochloride sustained release tablet and preparation method therefor |
| CN115108945A (en) * | 2022-07-14 | 2022-09-27 | 山东省分析测试中心 | Preparation method of metformin hydrochloride crystal and monodisperse rod-like crystal with uniform particle size obtained by adopting preparation method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009011451A1 (en) * | 2007-07-19 | 2009-01-22 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
| CN101450920A (en) * | 2007-11-30 | 2009-06-10 | 山东方兴科技开发有限公司 | Method for producing metformin hydrochloride large particle crystal |
| CN102153489A (en) * | 2011-02-21 | 2011-08-17 | 寿光富康制药有限公司 | Novel crystal form of metformin hydrochloride and preparation method thereof |
| EP2845590A1 (en) * | 2013-09-06 | 2015-03-11 | Biokier, Inc. | Composition for treatment of diabetes |
-
2016
- 2016-06-12 CN CN201610409379.0A patent/CN106008277A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009011451A1 (en) * | 2007-07-19 | 2009-01-22 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
| CN101450920A (en) * | 2007-11-30 | 2009-06-10 | 山东方兴科技开发有限公司 | Method for producing metformin hydrochloride large particle crystal |
| CN102153489A (en) * | 2011-02-21 | 2011-08-17 | 寿光富康制药有限公司 | Novel crystal form of metformin hydrochloride and preparation method thereof |
| EP2845590A1 (en) * | 2013-09-06 | 2015-03-11 | Biokier, Inc. | Composition for treatment of diabetes |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017195086A1 (en) * | 2016-05-10 | 2017-11-16 | Sarath Kumar Kamavarapu | Salts of n,n-dimethylbiguanide and preparation methods thereof |
| CN108864100A (en) * | 2018-08-02 | 2018-11-23 | 中国海洋大学 | A kind of salt, preparation method and the crystal structure of mercaptopurine and melbine |
| CN108864100B (en) * | 2018-08-02 | 2021-04-23 | 中国海洋大学 | Salt of mercaptopurine and metformin, preparation method and crystal structure thereof |
| WO2022148053A1 (en) * | 2021-01-05 | 2022-07-14 | 海南海力制药有限公司 | Purification method for metformin hydrochloride, metformin hydrochloride sustained release tablet and preparation method therefor |
| CN115108945A (en) * | 2022-07-14 | 2022-09-27 | 山东省分析测试中心 | Preparation method of metformin hydrochloride crystal and monodisperse rod-like crystal with uniform particle size obtained by adopting preparation method |
| CN115108945B (en) * | 2022-07-14 | 2024-05-17 | 山东省分析测试中心 | Preparation method of metformin hydrochloride crystal and monodisperse rod-shaped crystal with uniform granularity obtained by adopting method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002344419B2 (en) | Alpha-form or beta-form cyrstal of acetanilide derivative | |
| CA2665048C (en) | Crystalline forms of thiazolidinedione compound and its manufacturing method | |
| JP5467040B2 (en) | 1/2 fumarate salt of pyrazole derivative | |
| CN106008277A (en) | Novel metformin hydrochloride and preparing method thereof | |
| BR112015006075B1 (en) | CRYSTALLINE COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF CRYSTALLINE COMPOUND, CRYSTALLINE HYDRATE OF VORTIOXETINE HYDRATE, METHOD FOR THE PREPARATION OF CRYSTALLINE HYDRATE OF VORTIOXETINE HYDRATE, METHOD FOR THE PREPARATION OF THE CRYSTALLINE COMPOUND AND USE OF CRYSTALLINE HYDRATE VORTIOXETINE HYDRATE | |
| BRPI0702875A2 (en) | crystalline forms of tigecycline and their preparation processes | |
| JP2009143954A (en) | Thiazolidinedione derivative and its use as antidiabetic drug | |
| CN107501262A (en) | GRAPIPRANT crystal form | |
| CN104230907A (en) | Method for preparing crystals and application of crystals | |
| CN103936726A (en) | Crystal, preparation method and applications of crystal | |
| CN108239055B (en) | THR 1442L-aspartic acid eutectic crystal, preparation method and pharmaceutical composition thereof | |
| JP2023528565A (en) | Crystal Form A of GLP-1 Receptor Agonist and Method for Preparing The Same | |
| CN109438370B (en) | Methylpyrazine derivative anhydrous crystal form | |
| WO2014101865A1 (en) | Composition of glucose derivative and proline, crystal, preparation method and application | |
| WO2012147832A1 (en) | Phenyl pyrrole derivative crystal | |
| TWI664172B (en) | Crystal form of lenalidomide, preparation method and application thereof | |
| TWI705065B (en) | Salt of morpholine derivative and its crystal form, manufacturing method thereof, pharmaceutical composition and use thereof | |
| CN105566314A (en) | Tizanidine hydrochloride compound | |
| WO2002083633A1 (en) | Suplatast tosilate crystals | |
| JP7322151B2 (en) | Pharmaceutical compounds, methods for their manufacture, and uses as drugs | |
| JP7359769B2 (en) | Salts of pyranose-substituted heterocyclic compounds, their preparation methods and uses | |
| CN104768927B (en) | (3S, 3S ') 4,4 ' disulphanes diyls double (sulfonic acid of 3 butylamine 1) close the new crystalline phase of L lysines | |
| US10654820B2 (en) | Crystal form of tasimelteon | |
| CN105985252B (en) | Ornithine aspartate crystal form IV and preparation method thereof | |
| CN112409285A (en) | Crystal form of oxazolidinone compound, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161012 |